The FDA has recently approved two new prophylactic treatments for people with hemophilia who develop antibodies to clotting ...

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.

Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China… ...

Sanofi's rilzabrutinib receives FDA orphan drug designation for two rare diseases. Clinical studies show meaningful response ...

The U.S. Food and Drug Administration has approved Sanofi's Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce ...

The approval came on the basis of two randomized clinical trials that had 177 adult and pediatric male patients with either ...

After being stranded in space for more than nine months, two NASA astronauts are finally jetting back into the Earth's atmosphere. Suni Williams and Butch Wilmore are due to splash down off ...

Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.

The FDA has approved fitusiran, now Qfitlia, as a treatment for hemophilia A or B patients, ages 12 and older, with or ...

Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper hand.

Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.

The U.S. Food and Drug Administration on Friday approved Sanofi SA’s (NASDAQ:SNY) Qfitlia (fitusiran), the first antithrombin ...